Association of Endothelial Nitric Oxide Synthase and Angiotensin-Converting Enzyme Genes Polymorphism With In-Sent Restenosis of Bare Metal Stents vs Drug-Eluting Stents in Egyptians
Restricted accessResearch articleFirst published online May, 2025
Association of Endothelial Nitric Oxide Synthase and Angiotensin-Converting Enzyme Genes Polymorphism With In-Sent Restenosis of Bare Metal Stents vs Drug-Eluting Stents in Egyptians
Despite its unequivocal superiority compared with balloon angioplasty, coronary stenting did not abolish restenosis. We aimed to evaluate the associations between a common single nucleotide polymorphism occurring in endothelial nitric oxide synthase (eNOS) and angiotensin-converting enzyme (ACE) genes and the risk of in-stent restenosis (ISR) of bare metal stents vs drug-eluting stents (BMS vs DES) implanted in Egyptian patients. Two hundred patients who had coronary stenting were divided into group I (n = 98) who received a BMS and group II (n = 102) who received a DES. eNOS and ACE genes polymorphism were analyzed by polymerase chain reaction (PCR). We found that the GA and AA genotypes of the eNOS gene were associated with the ISR with both BMS and DES. However, the ACE gene was not associated with ISR. We concluded that eNOS gene polymorphism is associated with ISR. Hypertension, stent length, and AA genotype of the eNOS gene were found to be independent predictors of the occurrence of ISR after both BMS and DES use.
BergheanuSCPonsDKaralisI, et al.Genetic determinants of adverse outcomes (restenosis, malposition, and thrombosis) after stent implantation. Intervent Cardiol. 2010; 2: 147–157.
2.
WilsonSMonePKansakarU, et al.Diabetes and restenosis. Cardiovasc Diabetol. 2022;21:23.
3.
ZhouJChaiDDaiY, et al.Predictive value analysis of in-stent restenosis within three years in older acute coronary syndrome patients: a two-center retrospective study. Clin Appl Thromb Hemost. 2022; 28: 1–9.
4.
YuHDaiJFangC, et al.Prevalence, morphology, and predictors of intra-stent plaque rupture in patients with acute coronary syndrome: an optical coherence tomography study. Clin Appl Thromb Hemost. 2022; 28: 1–8.
5.
NakazawaGOtsukaFNakanoM, et al.The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57:1314–1322.
6.
NomotoYNakagawaMShiraiN, et al.Neointimal coverage after second generation drug-eluting stent implantation has a relationship with pre-existing atherosclerotic lesion characteristics. Medicine. 2019; 98:37.
7.
SinghIMFilbySJSakrFE, et al.Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis. Cathet Cardiovasc Interv. 2010; 75: 338–342.
8.
MonraatsPSPiresNMAgemaWR, et al.Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation. 2005; 112: 2417–2425.
9.
VerschurenJJTrompetSSampietroML, et al.Pathway analysis using genome-wide association study data for coronary restenosis – a potential role for the parvb gene. PLoS One. 2013; 8: e70676.
10.
SuzukiTOkumuraKSoneT, et al.The Glu298Asp polymorphism in endothelial nitric oxide synthase gene is associated with coronary in-stent restenosis. Int J Cardiol. 2002; 86: 71–76.
11.
JørgensenEKelbaekHHelqvistS, et al.Predictors of coronary in-stent restenosis: importance of angiotensin-converting enzyme gene polymorphism and treatment with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2001; 38: 1434–1439.
12.
SajadianMAlizadehLGanjifardM, et al.Factors affecting in-stent restenosis in patients undergoing percutaneous coronary angioplasty. GMJ. 2018; 7: e961.
13.
ByrneRAJonerMKastratiA. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Grüntzig Lecture ESC 2014. Eur Heart J. 2015; 36: 3320–3331.
14.
AlvarezRRegueroJRBatallaA, et al.Angiotensin-converting enzyme and angiotensin II receptor 1 polymorphisms: association with early coronary disease. Cardiovasc Res. 1998; 40: 375–379.
15.
Abdel-AzizTAMohamedRH. Association of endothelial nitric oxide synthase gene polymorphisms with classical risk factors in development of premature coronary artery disease. Mol Biol Rep. 2013; 40: 3065–3071.
16.
ChengGChangFJWangY, et al.Factors influencing stent restenosis after percutaneous coronary intervention in patients with coronary heart disease: a clinical trial based on 1-year follow-up. Med Sci Mon Int Med J Exp Clin Res. 2019; 25: 240–247.
17.
ParamasivamGDevasiaTUbaidS, et al.In-stent restenosis of drug-eluting stents: clinical presentation and outcomes in a real-world scenario. Egyptian Heart J. 2019; 71: 28.
18.
SimsekCMagroMBoersmaE, et al.The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) registries. JACC Cardiovasc Interv. 2010; 3: 1051–1058.
19.
StolkerJMKennedyKFLindseyJB, et al.Predicting restenosis of drug-eluting stents placed in real-world clinical practice: derivation and validation of a risk model from the EVENT registry. Circ Cardiovasc Interv. 2010; 3: 327–334.
20.
JukemaJWAhmedTAVerschurenJJ, et al.Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol. 2011;9:79–90.
21.
JakubiakGKPawlasNCieślarG, et al.Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int J Environ Res Publ Health. 2021; 18: 11970.
22.
ZholdybayevaEVTalzhanovYAAitkulovaAM, et al.Genetic risk factors for restenosis after percutaneous coronary intervention in Kazakh population. Hum Genom. 2016; 10: 15.
23.
ZhouSMuGWeiS, et al.Associations between polymorphisms of endothelial nitric oxide synthase, matrix metalloproteinase 3, angiotensinogen, and angiotensin II type 1 receptor and risk of restenosis after percutaneous coronary intervention: a meta-analysis. Clin Therapeut. 2020; 42: 458–474.
24.
ZengWPZhangRLiR, et al.Association of the endothelial nitric oxide synthase gene T786C polymorphism with in-stent restenosis in Chinese han patients with coronary artery disease treated with drug-eluting stent. PLoS One. 2017; 12: e0170964.
25.
OguriMKatoKHibinoT, et al.Genetic risk for restenosis after coronary stenting. Atherosclerosis. 2007; 194: e172–e178.
26.
GriendlingKKFitzGeraldGA. Oxidative stress and cardiovascular injury: Part II: animal and human studies. Circulation. 2003; 108: 2034–2040.
27.
ChoiYKKimY-M. Regulation of endothelial and vascular functions by carbon monoxide via crosstalk with nitric oxide. Front Cardiovasc Med. 2021; 8: 649630.
28.
SendesniRGriraNLamineO, et al.Endothelial nitric oxide synthase (eNOS) Glu298Asp gene polymorphism (G894T) as a risk factor for type 2 diabetes mellitus in the Tunisian population. Open Access Library J. 2018; 5: e4171.
29.
Khalkhali-EllisZHendrixMJ. Nitric oxide regulation of maspin expression in normal mammary epithelial and breast cancer cells. Am J Pathol. 2003;162:1411–1417.
30.
MiaoHWGongH. Association of ACE insertion or deletion polymorphisms with the risk of coronary restenosis after percutaneous coronary intervention: a meta-analysis. J Renin-Angiotensin-Aldosterone Syst JRAAS. 2015; 16: 844–850.
31.
VolzkeHHertwigSRettigR, et al.The angiotensinogen gene 235T variant is associated with an increased risk of restenosis after percutaneous transluminal coronary angioplasty. Clin Sci (Lond). 2000; 99: 19–25.
32.
AzovaMTimizhevaKAit AissaA, et al.Gene polymorphisms of the renin-angiotensin-aldosterone system as risk factors for the development of in-stent restenosis in patients with stable coronary artery disease. Biomolecules. 2021; 11: 763.
33.
SamaniNJMartinDSBrackM, et al.Insertion/deletion polymorphism in the angiotensin converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet. 1995; 345: 1013–1016.
34.
KochWKastratiAMehilliJ, et al.Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene is not associated with restenosis after coronary stent placement. Circulation. 2000; 102: 197–202.
35.
HamonMFradinSDenizetA, et al.Prospective evaluation of the effect of an angiotensin I converting enzyme gene polymorphism on the long term risk of major adverse cardiac events after percutaneous coronary intervention. Heart. 2003; 89: 321–325.
36.
AgemaWRJukemaJWZwindermanAH, et al.A meta-analysis of the angiotensin-converting enzyme gene polymorphism and restenosis after percutaneous transluminal coronary revascularization: evidence for publication bias. Am Heart J. 2002; 144: 760–768.
37.
BonniciFKeavneyBCollinsR, et al.Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies. BMJ. 2002; 325: 517–520.
38.
RathoreSTerashimaMKatohO, et al.Predictors of angiographic restenosis after drug eluting stents in the coronary arteries: contemporary practice in real world patients. EuroIntervention. 2009; 5: 349–354.
39.
PopmaJJDe CesareNBPinkertonCA, et al.Quantitative analysis of factors influencing late lumen loss and restenosis after directional coronary atherectomy. Am J Cardiol. 1993; 71: 552–557.
40.
BrownRAWilliamsMBarkerCM, et al.Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results. Cathet Cardiovasc Interv. 2010; 76: 804–813.
41.
CohenDJDoucetMCutlipDE, et al.Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker’s paradox?Circulation. 2001; 104: 773–778.
42.
SinghMGershBJMcClellandRL, et al.Clinical and angiographic predictors of restenosis after percutaneous coronary intervention: insights from the Prevention of Restenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation. 2004; 109: 2727–2731.
43.
BinderBR. Thrombin is bad, accepted; but is smoking good to prevent restenosis?J Thromb Haemostasis. 2006; 4: 2188–2190.
44.
WangPQiaoHWangR, et al.The characteristics and risk factors of in-stent restenosis in patients with percutaneous coronary intervention: what can we do. BMC Cardiovasc Disord. 2020; 20: 510.
45.
AronsonDBloomgardenZRayfieldEJ. Potential mechanisms promoting restenosis in diabetic patients. J Am Coll Cardiol. 1996; 27: 528–535.
46.
ChoiIJKohYSLimS, et al.Impact of the stent length on long-term clinical outcomes following newer-generation drug-eluting stent implantation. Am J Cardiol. 2014; 113: 457–464.
47.
StoneGWPariseHWitzenbichlerB, et al.Selection criteria for drug-eluting versus bare-metal stents and the impact of routine angiographic follow-up: 2-year insights from the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial. J Am Coll Cardiol. 2010; 56: 1597–1604.
48.
ZbindenRvon FeltenSWeinB, et al.Impact of stent diameter and length on in-stent restenosis after DES vs BMS implantation in patients needing large coronary stents—a clinical and health-economic evaluation. Cardiovasc Ther. 2017; 35: 19–25.
49.
MonePGambardellaJMinicucciF, et al.Hyperglycemia drives stent restenosis in STEMI patients. Diabetes Care. 2021; 44: e192–e193.
50.
ShlofmitzEIantornoMWaksmanR. Restenosis of drug-eluting stents A new classification system based on disease mechanism to guide treatment and state-of-the-art review. Circ Cardiovasc Interv. 2019; 12: e007023.
51.
OtsukaFVorpahlMNakanoM, et al.Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans. Circulation. 2014; 129: 211–223.
52.
YonetsuTKatoKKimSJ, et al.Predictors for neoatherosclerosis: a retrospective observational study from the optical coherence tomography registry. Circ Cardiovasc Imaging. 2012; 5: 660–666.
53.
GommaAHElrayessMAKnightCJ, et al.The endothelial nitric oxide synthase (Glu298Asp and –786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J. 2002; 23: 1955-1962.
54.
MaWYan LiangYZhuJ, et al.Relationship of paraoxonase-1 Q192R genotypes and in-stent restenosis and re-stenting in Chinese patients after coronary stenting. Atherosclerosis. 2016; 251: 305e–310e.
